European stocks advanced as Novo Nordisk shares rallied following news that a US competitor scrapped its copycat version of the Wegovy weight-loss pill. The pharmaceutical giant's stock gained momentum after the withdrawal of the competing product, which had threatened Novo's market dominance in the lucrative obesity treatment sector. Market analysts noted the development strengthens Novo's position in the rapidly expanding weight-loss drug market.

Wegovy, Novo Nordisk's blockbuster medication, has been a major driver of the company's recent growth, with demand surging as obesity rates climb globally. The removal of a competitor's copycat version eliminates a potential threat to Novo's market share and pricing power. European markets broadly gained ground, with the positive sentiment around Novo Nordisk contributing to overall gains in the pharmaceutical and healthcare sectors.

The development highlights the competitive dynamics in the weight-loss drug market, where Novo Nordisk and Eli Lilly have emerged as dominant players. Investors reacted positively to the news, viewing it as a validation of Novo's market position and growth prospects. The rally in Novo shares provided a significant boost to European indices, demonstrating the outsized influence of major pharmaceutical companies on broader market performance.